106 Kodiak Sciences Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) Year Ended December 31, 2018 Year Ended December 31, 2017 Year Ended December 31, 2016 Operating expenses Research and development .................................................................. $ 18,793 $ 22,022 $ 14,053 General and administrative.................................................................. 7,581 3,499 3,098 Total operating expenses................................................................ 26,374 25,521 17,151 Loss from operations................................................................................. (26,374) (25,521) (17,151) Interest expense (includes $3,030 and $914 attributable to related parties for the years ended December 31, 2018 and 2017, respectively)..................................................................... (5,519) (1,185) (6) Other income (expense), net (includes $2,736 and $1,008 attributable to related parties for the years ended December 31, 2018 and 2017, respectively ) ................................... (4,071) (1,230) 25 Loss on extinguishment of debt (includes $1,587 attributable to related parties for the year ended December 31, 2018).................... (5,479) — — Net loss and comprehensive loss .............................................................. $ (41,443) $ (27,936) $ (17,132) Net loss per share attributable to common stockholders, basic and diluted..................................................................................... $ (2.77) $ (3.72) $ (2.38) Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted......... 14,976,515 7,515,336 7,211,360 The accompanying notes are an integral part of these consolidated financial statements.